The trajectory of companies tied to the drug's history presents a challenging investment landscape. While the initial surge generated substantial returns , generic copies have significantly eroded market share . Investing in connected pharmaceutical firms now requires a careful assessment of proprietary safeguards, evolving healthcare trends , and